loading page

Ketamine in Pediatric Oncology: a drug review
  • Satya Prakash,
  • Aditya Gupta,
  • J Meena
Satya Prakash
All India Institute of Medical Sciences
Author Profile
Aditya Gupta
All India Institute of Medical Sciences
Author Profile
J Meena
All India Institute of Medical Sciences
Author Profile

Abstract

Ketamine is a dissociative anesthetic agent, with excellent analgesic properties and a favorable safety profile. Although it acts predominantly through NMDA receptor antagonism, numerous other molecular targets have been characterized, rendering anti-inflammatory, anti-depressant, and thus expanding its scope for new clinical applications. The noticeable safety of ketamine in children enables its widespread use in pediatric oncology, chiefly for procedural sedation. Its value for chronic pain management in children with cancer is being increasingly recognized but requires more evidence. The topical use of ketamine is largely in investigational stages.. Rational medical use of ketamine is largely free from significant long-term neurological side effects but may have some troublesome short-term effects such as vomiting, palpitations, urinary retention, and hallucinations. This review will provide a brief account of the pharmacology of ketamine and primarily focus on the relevant aspects of ketamine in pediatric oncology.

Peer review status:ACCEPTED

25 Aug 2020Submitted to Pediatric Blood & Cancer
25 Aug 2020Submission Checks Completed
25 Aug 2020Assigned to Editor
31 Aug 2020Reviewer(s) Assigned
05 Sep 2020Review(s) Completed, Editorial Evaluation Pending
15 Sep 2020Editorial Decision: Revise Major
27 Sep 2020Submission Checks Completed
27 Sep 2020Assigned to Editor
27 Sep 20201st Revision Received
28 Sep 2020Reviewer(s) Assigned
29 Sep 2020Review(s) Completed, Editorial Evaluation Pending
13 Oct 2020Editorial Decision: Revise Minor
16 Oct 20202nd Revision Received
16 Oct 2020Submission Checks Completed
16 Oct 2020Assigned to Editor
19 Oct 2020Review(s) Completed, Editorial Evaluation Pending
19 Oct 2020Editorial Decision: Accept